By LunitLearning Objectives
- Understand Lunit's two product lines: cancer screening and oncology biomarkers
- Identify how OEM distribution gives Lunit global reach
- Evaluate what a publicly traded pure-play signals about medical-AI maturity
What Is Lunit?
Lunit is a publicly traded (KOSDAQ) South Korean medical-AI company focused on cancer — both detecting it on medical images and guiding oncology treatment. Its INSIGHT product line applies deep learning to chest X-rays (nodule and abnormality detection and triage) and mammography (breast-cancer detection), while its SCOPE line analyzes pathology images for immuno-oncology biomarkers that help predict which patients will respond to certain cancer therapies. The tools are FDA-cleared and CE-marked, deployed across dozens of countries.
What distinguishes Lunit is distribution: beyond selling directly to hospitals, it embeds its AI inside imaging devices from original-equipment-manufacturer partners, giving it reach into clinics worldwide through the hardware they already buy. As one of the few publicly traded pure-play medical-AI companies, Lunit is a useful bellwether for the commercial maturity of cancer-screening AI. Its 2024 acquisition of New Zealand-based Volpara Health added a large US breast-screening footprint and data assets. The company's dual focus — screening AI plus oncology biomarkers — spans both radiology and pathology, and it faces the usual detection-AI caveats: clearances are indication-specific, performance depends on image quality and population, and human reads remain in the loop.
💡Key Concept
Two lines, one disease: Lunit attacks cancer from two directions — INSIGHT finds it earlier on screening images, and SCOPE analyzes pathology to guide which treatment is most likely to work. Detection and treatment guidance, under one company.
📝Note
Why OEM distribution matters: By embedding its AI inside partners' imaging devices, Lunit reaches clinics through hardware they already purchase — a scalable route to global deployment that direct hospital sales alone cannot match.
✅Tip
Visit Lunit: lunit.io — sold directly and through imaging-device partners; publicly listed on the KOSDAQ exchange.
Pricing
Lunit sells through hospital agreements and OEM partnerships rather than public list pricing; screening AI is typically licensed by volume or embedded in partner devices, while biomarker analysis is billed as an oncology service.
- Chest X-ray and mammography AI
- Direct or OEM-embedded
- Volume-based licensing
- Pathology biomarker analysis
- Therapy-response insight
- Service-based billing
Core Features
INSIGHT Chest X-Ray and Mammography
Detects and triages cancer-relevant findings on chest X-rays and mammograms, supporting earlier detection in high-volume screening programs.
SCOPE Oncology Biomarkers
Analyzes pathology images to quantify immuno-oncology biomarkers that help predict response to certain cancer therapies, connecting imaging to treatment decisions.
OEM-Embedded Distribution
Embeds its AI inside imaging devices from manufacturing partners, extending global reach through hardware clinics already buy.
Global, Cleared Footprint
FDA-cleared and CE-marked products deployed across dozens of countries, strengthened in the US breast-screening market by the Volpara acquisition.
Strengths
- Cancer-focused across radiology and pathology — detection plus treatment guidance
- Global distribution — direct sales plus OEM-embedded reach
- Publicly traded pure-play — a bellwether for medical-AI commercial maturity
- US breast-screening footprint — expanded via the 2024 Volpara acquisition
- Regulatory breadth — FDA-cleared and CE-marked products
Limitations and Considerations
- Indication-specific clearances — each covers a defined finding and use
- Image-quality and population dependence — accuracy varies with input and setting
- Human-in-the-loop — supports rather than replaces the radiologist or pathologist
- Commercial execution — as a listed company, adoption must translate into sustainable revenue
- Biomarker evidence evolving — therapy-response prediction is an active research area
Best Use Cases
| Use Case | Why Lunit Fits | Caveat |
|---|---|---|
| Breast-cancer screening programs | Mammography AI with a US footprint | Radiologist confirms the read |
| Chest X-ray screening at scale | INSIGHT detection and triage | Indication-specific clearances |
| Immuno-oncology treatment selection | SCOPE biomarker analysis | Evidence base still evolving |
| OEM-integrated imaging deployments | AI embedded in partner devices | Depends on partner hardware |
Key Takeaways
- Lunit is a publicly traded South Korean cancer-detection AI company spanning radiology screening (INSIGHT) and oncology pathology biomarkers (SCOPE)
- INSIGHT detects cancer on chest X-rays and mammograms; SCOPE analyzes pathology to guide immuno-oncology treatment
- OEM-embedded distribution gives Lunit global reach beyond direct hospital sales, and the 2024 Volpara acquisition added a US breast-screening footprint
- As one of few listed pure-play medical-AI companies, it is a bellwether for the field's commercial maturity
- Standard detection-AI caveats apply: indication-specific clearances, quality and population dependence, and human-in-the-loop reads
